Document is current
Any future updates will be listed below
-
Authors
Cooperrider, Jennifer H.
Karaoglu, Diren Arda
Kubicki, Tadeusz https://orcid.org/0000-0001-7588-1453
Jiang, Can Rui
Postich, Ella
Shimamoto, Kathryn https://orcid.org/0000-0002-2732-6495
Arnold, Olivia
Macaraeg, Jommel https://orcid.org/0000-0002-6307-5056
Ramsland, Aubrianna
Pula, Anna https://orcid.org/0000-0003-2270-2997
Kishtagari, Ashwin
Pershad, Yash
Mack, Taralynn M.
Jones, Angela https://orcid.org/0000-0002-1565-4360
Bick, Alexander G. https://orcid.org/0000-0001-5824-9595
Savona, Michael https://orcid.org/0000-0003-3763-5504
Drazer, Michael W.
Dytfeld, Dominik
Jakubowiak, Andrzej https://orcid.org/0000-0002-2597-6822
Derman, Benjamin A. https://orcid.org/0000-0002-4070-1819
Saygin, Caner https://orcid.org/0000-0001-7617-8356
-
Funding
Funding for this research was provided by:
American Society of Hematology
- License Information
-
More Information
Article History
Received: 7 March 2025
Revised: 11 June 2025
Accepted: 7 July 2025
First Online: 16 July 2025
Competing interests
: The authors declare no competing interests.
: This study adhered to the ethical guidelines set by institutional and/or national research committees and complied with the principles outlined in the Declaration of Helsinki. All methods followed the applicable guidelines and regulations. The University of Chicago Institutional Review Board has approved the MRD2STOP and ATLAS clinical trials and the correlative research conducted with these samples. All participants provided written informed consent.
